WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-10 10:25 am Purchase |
2024-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 6,950,567 7.500% |
2,490,876 (+55.85%) |
Filing |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 4,459,691 5.570% |
1,214,586 (+37.43%) |
Filing |
| 2024-02-08 10:11 am Purchase |
2023-12-29 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 3,245,105 4.860% |
440,620 (+15.71%) |
Filing |
| 2023-02-06 2:51 pm Purchase |
2022-12-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 2,804,485 5.210% |
2,804,485 (New Position) |
Filing |